Acute Coronary Syndromes (ACS)

heartwire News

  • New Health Insurer Policy May Mean Patients Pay for ER Visit With the price of emergency room care going up, U.S. insurance companies have been looking for ways to contain the costs - sometimes by refusing to pay for visits that turn out not to have been emergencies after all.
  • Cardiotoxicity Common With Angiogenesis Inhibitors Tyrosine kinase inhibitors that target vascular endothelial growth factor receptor (VEGFR-TKIs) are commonly associated with cardiovascular toxicity.
  • Complete PCI Linked to Better Long-term Survival in NSTEMI The observational results need to be confirmed in a randomized trial, experts agree, but advance the debate over the optimal approach to patients with NSTEMI and multivessel disease.
  • ACEP 2018 Hospital Reporting Unrelated to Better Patient Outcomes There is a broad consensus that measuring quality is important, but new emergency medicine data call some of these processes into question because they might not be improving patient care.

Perspective

  • Requiem for Aspirin in Dual Antiplatelet Therapy?   Mounting evidence makes Dr Michelle O'Donoghue wonder whether the perennial question on the optimal duration of DAPT should be revised to: How soon can you drop the aspirin? Have you changed your practice?
  • TCT 2018 MitraClip for Secondary MR -- The Redux Two conflicting studies on the percutaneous treatment of secondary mitral regurgitation in patients with heart failure lead John Mandrola, MD, to compare and contrast as we await the tiebreaker third.
  • Beta-Blockade After MI: No Practice Should Be Set in Stone Meta-analyses suggest little benefit for beta-blockers in contemporary patients with normal ejection fraction after MI. What other dogma should be revisited in light of an evolving evidence base?
  • ESC 2018 Will GLOBAL LEADERS Change Dual Antiplatelet Therapy Regimens?   Drs Christopher Granger and Adnan Kastrati discuss the implications of the GLOBAL LEADERS trial comparing ticagrelor monotherapy with DAPT 1 year after stenting for acute or stable coronary disease.